Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tigecycline

FDA-approved product (powder, intravenous), marketed as Tigecycline, Tygacil.

Registered studies
50+
Lab records
152
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Tigecycline
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Infection
  • Skin disease caused by bacterial infection
  • Skin disorder caused by infection
  • Soft Tissue Infections

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Tetracyclines
FDA pharmacologic class
Tetracycline-class Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01AA12; FDA class Tetracycline-class Antibacterial

Repurposing investigation

Tigecycline is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA88.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli78.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae99.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis62.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • K. pneumoniae: measured active in 152 of 152 lab records
Open Tigecycline in ChEMBL Registered studies below
Show the latest 150 of 152 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tigecycline with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial

    NCT07485010 · start 2027-04

    Registered record
    Registry ID
    NCT07485010
    Conditions
    Mycobacterium Abscessus Pulmonary Disease; Mycobacterium Abscessus Infection; Non-Tuberculous Mycobacterial (NTM) Infections; Non-Tuberculous Mycobacteria Pulmonary Disease
    Interventions
    Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours); Ceftriaxone for Injection; Amoxicillin; Azithromcyin; clarithromycin; Clofazimine; Ethambutol; Amikacin Injection; tigecycline; Imipenem + Cilastatin; Cefoxitin; Amikacin (Inhalation); linezolid; Trimethoprim / Sulfamethoxazole; Doxycycline; moxifloxacin; bedaquiline; Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2027-04
    Completion
    2031-07
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycobacterium Abscessus Pulmonary Disease; Mycobacterium Abscessus Infection; Non-Tuberculous Mycobacterial (NTM) Infections; Non-Tuberculous Mycobacteria Pulmonary Disease
    InterventionSulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours); Ceftriaxone for Injection; Amoxicillin; Azithromcyin +14 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase Producing Enterobacterales Undergoing Liver Transplantation

    NCT07759453 · start 2026-10-01

    Registered record
    Registry ID
    NCT07759453
    Conditions
    Liver Transplant; Carbapenem-resistant Enterobacterales; CRE Colonization
    Interventions
    Ceftazidime - Avibactam ( CAZ-AVI); Meropenem-Vaborbactam; Imipenem+Relebactam; Cefiderocol; Aztreonam; Eravacycline; Aztreonam-Avibactam; Amoxi Clavulanate; Piperacillin + Tazobactam; Tigecycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-10-01
    Completion
    2029-09-30
    Enrolment
    168

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Transplant; Carbapenem-resistant Enterobacterales; CRE Colonization
    InterventionCeftazidime - Avibactam ( CAZ-AVI); Meropenem-Vaborbactam; Imipenem+Relebactam; Cefiderocol +6 more
    PhasePhase 3
    Registry statusNot yet recruiting

  • Epidemiology of Antimicrobial-use and Antimicrobial-resistant Infections in Four Hospitals in Thailand

    NCT07082465 · start 2025-12-01

    Registered record
    Registry ID
    NCT07082465
    Conditions
    Drug Resistance; Bacterial; Bacteremia
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2025-12-01
    Completion
    2027-11-30
    Enrolment
    108,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Resistance; Bacterial; Bacteremia
    InterventionNot recorded
    PhaseNot recorded
    Registry statusActive not recruiting

  • Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections

    NCT07089186 · start 2025-04-12

    Registered record
    Registry ID
    NCT07089186
    Conditions
    Hospital-acquired Bacterial Pneumonia (HABP); Ventilator-associated Bacterial Pneumonia (VABP); Complicated Intra-abdominal Infection (cIAI); Complicated Urinary Tract Infection (cUTI); Bloodstream Infection (BSI)
    Interventions
    Meropenem and Pralurbactam; Best Available Therapy (e.g., colistin, meropenem, tegecycline, amikacinceftezidime-avibatam)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-04-12
    Completion
    2027-04
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHospital-acquired Bacterial Pneumonia (HABP); Ventilator-associated Bacterial Pneumonia (VABP); Complicated Intra-abdominal Infection (cIAI); Complicated Urinary Tract Infection (cUTI) +1 more
    InterventionMeropenem and Pralurbactam; Best Available Therapy (e.g., colistin, meropenem, tegecycline, amikacinceftezidime-avibatam)
    PhasePhase 3
    Registry statusRecruiting

  • Comparing Tigecycline Vs. Colistimethate in CNS Infections

    NCT06702943 · start 2024-12-01

    Registered record
    Registry ID
    NCT06702943
    Conditions
    Central Nervous System Infections
    Interventions
    Tigecycline (Tygacil); Colistimethate sodium (CMS)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2024-12-01
    Completion
    2027-06
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCentral Nervous System Infections
    InterventionTigecycline (Tygacil); Colistimethate sodium (CMS)
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Predictors of Antimicrobial Resistance in the Respiratory Intensive Care Unit of Alexandria Main University Hospital

    NCT06750744 · start 2024-10-01

    Registered record
    Registry ID
    NCT06750744
    Conditions
    Identify the Predictors of Antibiotic Resistance
    Interventions
    chest x ray; chest X ray; Tigecycline (Tygacil)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2024-10-01
    Completion
    2024-12-12
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdentify the Predictors of Antibiotic Resistance
    Interventionchest x ray; chest X ray; Tigecycline (Tygacil)
    PhaseNot recorded
    Registry statusCompleted

  • Clinical Effectiveness of a Once-daily Regimen of Tigecycline Compared to the Standard Regimen

    NCT07258225 · start 2024-04-01

    Registered record
    Registry ID
    NCT07258225
    Conditions
    Multi Drug Resistant Infections
    Interventions
    Tigecycline once daily regimen; Usual doses of tigecycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2024-04-01
    Completion
    2026-04-30
    Enrolment
    86

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMulti Drug Resistant Infections
    InterventionTigecycline once daily regimen; Usual doses of tigecycline
    PhasePhase 4
    Registry statusActive not recruiting

  • The Efficacy and Adverse Reactions of Neotetracycline in the Treatment of GNB Infections

    NCT06990126 · start 2024-03-01

    Registered record
    Registry ID
    NCT06990126
    Conditions
    Clinical Efficacy and Safety
    Interventions
    bronchoscope
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Enrolling by invitation
    Start
    2024-03-01
    Completion
    2026-07-30
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClinical Efficacy and Safety
    Interventionbronchoscope
    PhaseNot recorded
    Registry statusEnrolling by invitation

  • Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection

    NCT06051513 · start 2023-11-27

    Registered record
    Registry ID
    NCT06051513
    Conditions
    Carbapenem-Resistant Enterobacteriaceae Infection
    Interventions
    treatment with or without colistin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2023-11-27
    Completion
    2025-12-31
    Enrolment
    404

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarbapenem-Resistant Enterobacteriaceae Infection
    Interventiontreatment with or without colistin
    PhaseNot applicable
    Registry statusRecruiting

  • Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies

    NCT05850871 · start 2023-01-06

    Registered record
    Registry ID
    NCT05850871
    Conditions
    Carbapenem-Resistant Enterobacteriaceae Infection
    Interventions
    CAZ/AVI plus Aztreonam; Conventional treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-01-06
    Completion
    2025-01-31
    Enrolment
    427

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarbapenem-Resistant Enterobacteriaceae Infection
    InterventionCAZ/AVI plus Aztreonam; Conventional treatment
    PhaseNot applicable
    Registry statusUnknown

  • Clinical Study of New Intensive Treatment Regimen for Severe Nontuberculous Mycobacterial Pulmonary Disease

    NCT05494957 · start 2022-08-05

    Registered record
    Registry ID
    NCT05494957
    Conditions
    Nontuberculous Mycobacterial Lung Disease
    Interventions
    New regimen(BdqCfzLzd+XY)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-08-05
    Completion
    2025-08-05
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNontuberculous Mycobacterial Lung Disease
    InterventionNew regimen(BdqCfzLzd+XY)
    PhasePhase 4
    Registry statusUnknown

  • Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults

    NCT04882085 · start 2021-08-26

    Registered record
    Registry ID
    NCT04882085
    Conditions
    Urinary Tract Infection; Acute Pyelonephritis; Hospital Acquired Pneumonia; Ventilator-associated Pneumonia; Bacteremia; Intra-abdominal Infection
    Interventions
    Zavicefta, Ceftazidime-Avibactam; Best Available Treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-08-26
    Completion
    2023-08-31
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infection; Acute Pyelonephritis; Hospital Acquired Pneumonia; Ventilator-associated Pneumonia +2 more
    InterventionZavicefta, Ceftazidime-Avibactam; Best Available Treatment
    PhasePhase 4
    Registry statusCompleted

  • Population Pharmacokinetics and Dosage Individualization of Antibiotics in Elderly Patients

    NCT04799626 · start 2021-04-01

    Registered record
    Registry ID
    NCT04799626
    Conditions
    Elderly Infection
    Interventions
    biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2021-04-01
    Completion
    2023-06-30
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionElderly Infection
    Interventionbiapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc
    PhaseNot recorded
    Registry statusUnknown

  • Personalized Treatment of Urogenital Cancers Depends on the Microbiome

    NCT03962920 · start 2020-05-01

    Registered record
    Registry ID
    NCT03962920
    Conditions
    Microbial Disease
    Interventions
    Tigecycline 50 MG; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2020-05-01
    Completion
    2027-05-01
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMicrobial Disease
    InterventionTigecycline 50 MG; Placebo
    PhaseNot applicable
    Registry statusRecruiting

  • Finding the Optimal Regimen for Mycobacterium Abscessus Treatment

    NCT04310930 · start 2020-03-02

    Registered record
    Registry ID
    NCT04310930
    Conditions
    Pulmonary Disease Due to Mycobacteria (Diagnosis)
    Interventions
    Amikacin; Tigecycline; Imipenem; Cefoxitin; Azithromycin; Clarithromycin; Clofazimine; Ethambutol; Amikacin; Linezolid; co-trimoxazole; Doxycycline; Moxifloxacin; Bedaquiline; Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2020-03-02
    Completion
    2030-06-30
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Disease Due to Mycobacteria (Diagnosis)
    InterventionAmikacin; Tigecycline; Imipenem; Cefoxitin +11 more
    PhasePhase 2 / Phase 3
    Registry statusRecruiting